ADC Therapeutics (ADCT) EBT (2020 - 2026)
ADC Therapeutics' (ADCT) quarterly EBT came in at -$16.6 million in Q2 2026, up 70.09% year-over-year from -$9.7 million in Q2 2025, and up 49.75% quarter-over-quarter from -$33.0 million in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) EBT (2020 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EBT across 7 years of filings, most recently posting -$16.6 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.77 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.25 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.39 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.53 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 542.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -767.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 132.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -11.37 Mn |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | -16.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.57 Mn |
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -55.39 Mn |
| Mar 31, 2025 | -38.44 Mn |
| Sep 30, 2024 | -43.62 Mn |
| Jun 30, 2024 | -35.71 Mn |
| Mar 31, 2024 | -45.80 Mn |
| Sep 30, 2023 | -45.40 Mn |
| Jun 30, 2023 | -52.70 Mn |
| Mar 31, 2023 | -59.69 Mn |
| Sep 30, 2022 | -51.32 Mn |
| Jun 30, 2022 | -65.32 Mn |
| Mar 31, 2022 | -17.83 Mn |
| Sep 30, 2021 | -71.40 Mn |
| Jun 30, 2021 | -72.33 Mn |
| Mar 31, 2021 | -51.42 Mn |
| Sep 30, 2020 | -20.33 Mn |
| Jun 30, 2020 | -126.45 Mn |
| Mar 31, 2020 | -43.38 Mn |